• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    2/12/24 12:31:18 PM ET
    $ANTX
    $GNTA
    $INBS
    $NSTG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ANTX alert in real time by email

    Gainers

    • Renalytix (NASDAQ:RNLX) stock rose 490.4% to $2.25 during Monday's regular session. The market value of their outstanding shares is at $112.4 million.
    • Regencell Bioscience (NASDAQ:RGC) stock rose 39.91% to $10.39. The market value of their outstanding shares is at $135.2 million.
    • Genenta Science (NASDAQ:GNTA) shares increased by 31.84% to $4.14. The market value of their outstanding shares is at $75.4 million.
    • T2 Biosystems (NASDAQ:TTOO) stock rose 29.94% to $6.35. The company's market cap stands at $25.7 million.
    • Sangamo Therapeutics (NASDAQ:SGMO) stock moved upwards by 26.04% to $0.72. The company's market cap stands at $128.3 million.
    • Organovo Holdings (NASDAQ:ONVO) shares moved upwards by 25.55% to $1.13. The market value of their outstanding shares is at $11.3 million. As per the press release, Q3 earnings came out 2 days ago.

    Losers

    • AN2 Therapeutics (NASDAQ:ANTX) stock decreased by 75.0% to $5.01 during Monday's regular session. The company's market cap stands at $149.0 million.
    • InVivo Therapeutics Hldg (NASDAQ:NVIV) shares declined by 33.39% to $0.33. The company's market cap stands at $1.0 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares fell 28.95% to $1.08.
    • NanoString Technologies (NASDAQ:NSTG) shares declined by 22.18% to $0.18. The market value of their outstanding shares is at $8.6 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) stock decreased by 18.58% to $5.51. The company's market cap stands at $4.0 million. The company's, Q2 earnings came out yesterday.
    • OneMedNet (NASDAQ:ONMD) shares decreased by 18.18% to $0.9. The market value of their outstanding shares is at $29.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANTX
    $GNTA
    $INBS
    $NSTG

    CompanyDatePrice TargetRatingAnalyst
    Sangamo Therapeutics Inc.
    $SGMO
    11/7/2025$1.00Overweight → Equal Weight
    Barclays
    Sangamo Therapeutics Inc.
    $SGMO
    12/13/2024$7.00Hold → Buy
    Truist
    Sangamo Therapeutics Inc.
    $SGMO
    12/10/2024$10.00Buy
    H.C. Wainwright
    AN2 Therapeutics Inc.
    $ANTX
    8/9/2024In-line → Underperform
    Evercore ISI
    AN2 Therapeutics Inc.
    $ANTX
    8/9/2024$5.00 → $1.00Outperform → Market Perform
    Leerink Partners
    AN2 Therapeutics Inc.
    $ANTX
    7/3/2024$5.00Market Perform → Outperform
    Leerink Partners
    AN2 Therapeutics Inc.
    $ANTX
    4/2/2024$6.00Mkt Perform → Mkt Outperform
    JMP Securities
    AN2 Therapeutics Inc.
    $ANTX
    2/13/2024$23.00 → $7.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ANTX
    $GNTA
    $INBS
    $NSTG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Williams Sarah Joanne sold $347 worth of shares (327 units at $1.06), decreasing direct ownership by 0.49% to 66,848 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    3/5/26 6:55:23 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 14,004 shares, decreasing direct ownership by 2% to 651,406 units (SEC Form 4)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    2/26/26 9:40:11 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Head of Research & Technology Davis Gregory D covered exercise/tax liability with 5,951 shares, decreasing direct ownership by 3% to 185,111 units (SEC Form 4)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    2/26/26 9:40:07 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $GNTA
    $INBS
    $NSTG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

    Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced advancement of the rolling submission of a BLA

    3/9/26 8:05:00 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AN2 Therapeutics Announces $40 Million Private Placement Financing

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share and, in lieu of common stoc

    3/9/26 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

    Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a blood cancer characterized by overproduction of red blood cells in the bone

    3/3/26 4:00:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    $GNTA
    $INBS
    $NSTG
    SEC Filings

    View All

    AN2 Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Regulation FD Disclosure

    8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)

    3/9/26 9:43:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/25/26 9:15:25 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by AN2 Therapeutics Inc.

    SCHEDULE 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)

    2/17/26 6:54:12 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    $GNTA
    $INBS
    $NSTG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Casaburi Eric bought $39,262 worth of shares (20,475 units at $1.92) and was granted 90,000 shares (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:54:45 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ANTX
    $GNTA
    $INBS
    $NSTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sangamo Therapeutics downgraded by Barclays with a new price target

    Barclays downgraded Sangamo Therapeutics from Overweight to Equal Weight and set a new price target of $1.00

    11/7/25 8:28:38 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics upgraded by Truist with a new price target

    Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

    12/13/24 8:18:20 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

    12/10/24 11:58:57 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $GNTA
    $INBS
    $NSTG
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ANTX
    $GNTA
    $INBS
    $NSTG
    Leadership Updates

    Live Leadership Updates

    View All

    Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

    MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) in transformation to Saentra Forge (NASDAQ:SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry into defense technology manufacturing. The Company also provided an update on its ongoing evaluation of majority-control acquisition opportunities in regulated national-security sectors. Mr. Salvato previously served as Chief Executive Officer of Fiocchi Munizioni S.p.A. (CSG Group

    2/27/26 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

    BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

    3/11/25 7:00:00 AM ET
    $GRCE
    $MTNB
    $ONVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

    MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization. Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Health

    3/3/25 8:35:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ANTX
    $GNTA
    $INBS
    $NSTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care